Screener
Oruka Therapeutics, Inc. ORKA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock upon exercise of stock options and employee warrants | 1,698 | — |
| Proceeds from at-the-market offering, net of commissions | 38,902 | — |
| Net cash provided by financing activities | 40,600 | — |
| Net increase in cash and cash equivalents | 2,585 | 21,997 |
| Cash and cash equivalents at beginning of period | 46,935 | 61,575 |
| Cash and cash equivalents at end of period | $49,520 | $83,572 |
| Supplemental disclosures of non-cash financing activities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s financing cash flow?
- Oruka Therapeutics, Inc. (ORKA) reported financing cash flow of $40.6M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Oruka Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude